Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. CYRAMZA
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

CYRAMZA

Medicine - Posted on May 29 2020 - Updated on May 29 2020
Active substance (DCI)
  • ramucirumab
history (5)
  • 5/27/20

    CYRAMZA (ramucirumab)

    Remboursement non sollicité pour une nouvelle indication. Remboursement non sollicité dans le traitement des patients adulte...
    icône flèche
  • 4/1/20

    CYRAMZA (ramucirumab)

    Key points Favourable opinion for reimbursement in the first-line treatment of adult patients with metastatic non-small cell...
    CAV :
    54321
    icône flèche
  • 9/21/16

    CYRAMZA (ramucirumab), monoclonal antibody

    Moderate clinical benefit in combination with FOLFIRI chemotherapy (irinotecan, folinic acid and 5-fluorouracil) in the trea...
    CAV :
    54321
    icône flèche
  • 10/5/16

    CYRAMZA Cancer bronchique avancé (ramucirumab)

    Le laboratoire ne demande pas l’inscription dans l’indication : « en association avec le docétaxel, dans le traitement des p...
    icône flèche
  • 6/17/15

    CYRAMZA (ramucirumab), monoclonal antibody

    In gastric or gastro-oesophageal junction cancer: - In combination with paclitaxel, its actual benefit is moderate - In mono...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XC21
Manufacturer
LILLY FRANCE
Presentation

CYRAMZA 10 mg/ml, solution à diluer pour perfusion (code CIS : 63848228)
1 flacon(s) en verre de 10 ml (CIP : 34009 550 002 7 3)
1 flacon(s) en verre de 50 ml (CIP : 34009 550 002 9 7)
2 flacon(s) en verre de 10 ml (CIP : 34009 550 002 8 0)

All our publications
    Autoimmune diseases Digestive system cancers Drug therapy Respiratory tract cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
1VunjUP2ZfAB0Hy9